Drug delivery pump warning
This article was originally published in Clinica
Executive Summary
Home use of a terbutaline-filled pump to prevent premature labour is dangerous, claims the US National Women's Health Network. The group has asked the FDA to forbid Matria Healthcare from renting the device or, at least, warn doctors of terbutaline's risks and lack of proven efficacy. The NWHN claims at least two women died using the pumps; another eight or more suffered heart or lung problems; and one baby was born with heart damage linked to the pump and drug.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.